Jazz Pharmaceuticals (NASDAQ:JAZZ) Reaches New 12-Month High – Time to Buy?

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) shares hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $235.00 and last traded at $229.6950, with a volume of 98928 shares. The stock had previously closed at $227.84.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on JAZZ shares. Wells Fargo & Company raised their price objective on shares of Jazz Pharmaceuticals from $250.00 to $265.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Robert W. Baird set a $252.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Bank of America increased their target price on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Weiss Ratings reissued a “sell (d+)” rating on shares of Jazz Pharmaceuticals in a report on Friday, March 27th. Finally, Royal Bank Of Canada upped their price objective on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $230.56.

Jazz Pharmaceuticals Trading Up 0.9%

The company has a quick ratio of 1.85, a current ratio of 2.04 and a debt-to-equity ratio of 0.95. The company has a market cap of $14.43 billion, a price-to-earnings ratio of -11,492.25, a P/E/G ratio of 0.40 and a beta of 0.27. The business has a fifty day simple moving average of $194.65 and a 200 day simple moving average of $174.83.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. The firm had revenue of $1.07 billion during the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. On average, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 20.67 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CAO Patricia Carr sold 1,287 shares of the firm’s stock in a transaction on Monday, March 9th. The stock was sold at an average price of $182.94, for a total value of $235,443.78. Following the completion of the transaction, the chief accounting officer owned 6,512 shares in the company, valued at $1,191,305.28. This trade represents a 16.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Mary Elizabeth Henderson sold 5,343 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $194.49, for a total value of $1,039,160.07. Following the transaction, the senior vice president directly owned 28,728 shares of the company’s stock, valued at $5,587,308.72. This trade represents a 15.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 74,015 shares of company stock worth $14,180,486. 4.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP increased its stake in shares of Jazz Pharmaceuticals by 11.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company’s stock worth $373,855,000 after purchasing an additional 298,815 shares in the last quarter. Capital World Investors raised its position in shares of Jazz Pharmaceuticals by 4.4% in the fourth quarter. Capital World Investors now owns 2,666,602 shares of the specialty pharmaceutical company’s stock valued at $453,322,000 after buying an additional 111,735 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in shares of Jazz Pharmaceuticals by 11.4% during the second quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock valued at $198,159,000 after buying an additional 191,637 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Jazz Pharmaceuticals by 8.5% during the third quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company’s stock valued at $246,092,000 after buying an additional 145,865 shares during the period. Finally, Franklin Resources Inc. grew its stake in Jazz Pharmaceuticals by 164.0% in the 4th quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock worth $309,215,000 after acquiring an additional 1,129,995 shares during the period. 89.14% of the stock is owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.